Dow Jones Top Company Headlines at 3 am ET: OpenAI Scraps Release of New AI Model over Safety Concerns | Novo ...

Dow Jones
Sep 29

OpenAI Scraps Release of New AI Model Over Safety Concerns

The model, dubbed GPT-6.1 Astra, was due to debut inside ChatGPT and Codex in October.

----

Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma

The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.

----

Hapag-Lloyd Raises Guidance Again on Strong Demand, Freight Rates

It cautioned, however, that freight rates are volatile and that the outlook is subject to a high degree of uncertainty given current and persistent geopolitical challenges.

----

Shein's Earnings Disappoint, Sending Stock Lower

The fast-fashion retailer's rocky start as a publicly listed continued as its first earnings since listing disappointed, sending its Hong Kong-listed stock down to a record low.

----

Google Appeals EU Requests on Android AI Access, Search Data Sharing

Google said it has filed appeals with the European Union's second-highest court against binding instructions to open up its Android operating system, allow other search engines to access search data.

----

Samsung Commits $1.0 Billion to AI Infrastructure Firm Backed by KKR, Nvidia

The investment in Helix Digital Infrastructure brings the platform's total secured capital to more than $11 billion.

----

Anthropic's potential $2 trillion IPO comes with the following fine print

Anthropic's revenue grew over 10-fold in 2025, but the cost of training and serving its models is also climbing.

----

Goldman's Board Has Discussed a Plan to Name John Waldron as Its Next CEO

Under the plan, David Solomon, who has led the bank since 2018, would step down as soon as next year and be executive chair.

----

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

----

Raytheon Gets $20.7 Billion Contract to Accelerate AMRAAM Missile Production

Under the five-year contract, with two option years, Raytheon said it will scale AMRAAM missile production to record levels to meet long-term demand.

----

AMD to Acquire World Labs for $8.2 Billion

The semiconductor company said the deal would help it develop better hardware, software and systems, especially in the growing field of physical AI and robotics.

----

Jefferies Stock Falls Despite Earnings Beat and Record Banking Revenue

Jefferies Financial Group reported a 16% increase in quarterly profit, but its shares slipped after hours.

----

FAA to Delay 737 MAX 10 Approval Over New Software Glitch

Air-safety regulators will assess a possible safety risk before certifying the longest and final model of Boeing's bestselling jet.

----

AAR to Pay $1.8 Billion for Stake in Aircraft-Maintenance Company

The aviation-services supplier agreed to buy a majority stake in the Bain-backed MRO Holdings.

----

The Nike Lifer Driving a High-Stakes Turnaround in China

Once one of its best markets, the country is now a major cause of the sportswear giant's sinking fortunes.

----

Meta Seeks Payoff From AI Spending With New Push for Business Customers

The tech giant is pushing to monetize its multibillion-dollar AI investments by selling more tools and services to companies.

----

SpaceX Launches Starship for First Orbital Mission

Starship entered orbit for the first time and deployed the latest version of Starlink satellites, critical steps in the company's push for the experimental rocket to handle a range of missions.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10